⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20376220 | 0.83 | EPHX1 (0.36) | — | |
| SCHEMBL4922033 | 0.81 | — | — | |
| SCHEMBL16629038 | 0.78 | — | — | |
| SCHEMBL3425515 | 0.78 | — | — | |
| SCHEMBL28304965 | 0.78 | — | — | |
| SCHEMBL23028911 | 0.76 | CYP2C19 (0.38) | — | |
| SCHEMBL9785056 | 0.75 | PRMT3 (0.32) | — | |
| SCHEMBL19103693 | 0.74 | — | — | |
| SCHEMBL27317515 | 0.74 | RELA (0.41) | — | |
| SCHEMBL28160546 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306572-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL InHIBITORS OF EGFR [ErbB1] AND HER-2 [ErbB2] | TRAGARA PHARMACEUTICALS, INC (US) | 2011-12-15 | — | — | US | claimed |
| EP-2205076-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL INHIBITORS OF EGFR ÝERBB1¨AND HER-2 ÝERBB2¨ | Tragara Pharmaceuticals, Inc. (US) | 2010-07-14 | — | — | EP | claimed |
| WO-2009042613-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER USING COX-2 INHIBITORS AND DUAL INHIBITORS OF EGFR [ERBB1] AND HER-2 [ERBB2] | TRAGARA PHARMACEUTICALS, INC. (US) | 2009-04-02 | — | — | WO | claimed |
| US-6828320-B2 | Enzyme inhibitors; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-07 | — | — | US | claimed |
| EP-0912559-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2002-11-06 | — | — | EP | claimed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | claimed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | claimed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | claimed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2023029928-A1 | AMINO LIPID AND APPLICATION THEREOF | 深圳虹信生物科技有限公司 | 2023-03-09 | — | — | WO | disclosed |
| US-20210300922-A1 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS | FAES FARMA, S.A. (ES) | 2021-09-30 | — | — | US | disclosed |
| WO-2020020939-A1 | PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS | FAES FARMA, S.A. (ES) | 2020-01-30 | — | — | WO | disclosed |
| US-10544095-B2 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | PFIZER INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-6828320-B2 | Enzyme inhibitors; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-07 | — | — | US | disclosed |
| EP-0912559-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2002-11-06 | — | — | EP | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |